Salving safety concerns

The trifecta of a novel adjuvant, a broad population and alternatives on the market sunk Dynavax Technologies Corp.'s first attempt to gain approval for its Heplisav HBV vaccine. The company thinks its best path to market may be to narrow the vaccine's target population.